Physician profile
Mark F Sullivan
NPI 1346669660
$3,581.05
in general payments reported to CMS, 2019-2025
27 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $543 · 2021: $397 · 2022: $232 · 2023: $1,154 · 2024: $879 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.16 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $444.68 | 2020-2025 | |
| Lilly USA, LLC | $442.17 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $349.28 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $258.91 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $200.60 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $140.49 | 2020-2021 | |
| Amgen INC. | $137.54 | 2020-2025 | Krystexxa |
| Exact Sciences Corporation | $113.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.42 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $91.55 | 2020-2023 | Xarelto |
| Vanda Pharmaceuticals INC. | $68.17 | 2020-2023 | Hetlioz |
| Astellas Pharma US INC | $65.29 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $62.50 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $54.50 | 2022-2023 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.17 | 2023-2024 | |
| Medicomp INC | $42.29 | 2023-2024 | Telepatch Cardiac Monitor |
| Xeris Pharmaceuticals, INC. | $41.58 | 2020 | |
| Esperion Therapeutics, INC. | $26.84 | 2020-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $25.37 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $24.21 | 2021 | |
| Becton, Dickinson and Company | $24.18 | 2025 | Bd Max System, Bd Max Instrument |
| Cumberland Pharmaceuticals, INC. | $24.14 | 2023 | Kristalose |
| Genentech USA, INC. | $23.19 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.76 | 2020 | |
| Watermark Medical, INC. | $18.82 | 2024 | |
| Medtronic, INC. | $16.52 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.